PF-03550096

PF-03550096
Identifiers
	IUPAC name N-[(1S)-1-(aminocarbonyl)-2,2-dimethylpropyl]-2,3-dihydro-3-(3-hydroxy-3-methylbutyl)-2-oxo-1H-benzimidazole-1-carboxamide;
CAS Number	910376-39-5 ;
PubChem CID	24857887;
CompTox Dashboard (EPA)	DTXSID001010008 ;
Chemical and physical data
Formula	C19H28N4O4
Molar mass	376.45 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N1C(N(CCC(C)(O)C)C2=C1C=CC=C2)=O)N[C@@H](C(C)(C)C)C(N)=O;

PF-03550096 is a drug that acts as a potent agonist for the CB₂ cannabinoid receptor, with good selectivity over CB₁ having K_i values of 7nM at CB₂ and 1500nM at CB₁. It was originally developed by Pfizer in 2008 as a medication for irritable bowel syndrome,^[1] but has only progressed to animal studies.^[2]

References

^ Ando K et al, BENZIMIDAZOLONE DERIVATIVES. WO 2008/032164
^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 18270474, please use {{cite journal}} with |pmid=18270474 instead.

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

[1] Ando K et al, BENZIMIDAZOLONE DERIVATIVES. WO 2008/032164

[2] Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 18270474, please use {{cite journal}} with |pmid=18270474 instead.

[1]

[2]

See also

References